The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy

被引：5
作者：
Yin, Yunfei [1 ]
Tan, Mingyue [1 ]
Han, Lianhua [1 ]
Zhang, Lei [1 ]
Zhang, Yue [1 ]
Zhang, Jun [1 ]
Pan, Wanqian [1 ]
Bai, Jiaxiang [1 ,2 ,3 ]
Jiang, Tingbo [1 ]
Li, Hongxia [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Dept Cardiol, Suzhou 215006, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou 215006, Peoples R China
[3] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Orthoped, Div Life Sci & Med, Hefei 230001, Peoples R China
来源：
ACTA PHARMACEUTICA SINICA B | 2023年 / 13卷 / 05期
关键词：
MST1; 2; kinases; Regulation; Apoptosis; Autophagy; Immune; Cardiovascular diseases; Metabolic diseases; Therapy; BETA-CELL APOPTOSIS; REGULATORY T-CELLS; STE20-LIKE PROTEIN-KINASE; ORGAN SIZE CONTROL; BECLIN; CHRONIC INFLAMMATION; TUMOR-SUPPRESSOR; AUTOPHAGY; ACTIVATION; PATHWAY;
D O I：
10.1016/j.apsb.2023.01.015
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cardiovascular diseases (CVDs) and metabolic disorders are major components of noncom-municable diseases, causing an enormous health and economic burden worldwide. There are common risk factors and developmental mechanisms among them, indicating the far-reaching significance in exploring the corresponding therapeutic targets. MST1/2 kinases are well-established proapoptotic effec-tors that also bidirectionally regulate autophagic activity. Recent studies have demonstrated that MST1/2 influence the outcome of cardiovascular and metabolic diseases by regulating immune inflammation. In addition, drug development against them is in full swing. In this review, we mainly describe the roles and mechanisms of MST1/2 in apoptosis and autophagy in cardiovascular and metabolic events as well as emphasis on the existing evidence for their involvement in immune inflammation. Moreover, we summa-rize the latest progress of pharmacotherapy targeting MST1/2 and propose a new mode of drug combi-nation therapy, which may be beneficial to seek more effective strategies to prevent and treat CVDs and metabolic disorders.@ 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码：1956 / 1975
页数：20
相关论文
共 230 条
[1]   The phenotype of human STK4 deficiency [J].
Abdollahpour, Hengameh ;
Appaswamy, Giridharan ;
Kotlarz, Daniel ;
Diestelhorst, Jana ;
Beier, Rita ;
Schaeffer, Alejandro A. ;
Gertz, E. Michael ;
Schambach, Axel ;
Kreipe, Hans H. ;
Pfeifer, Dietmar ;
Engelhardt, Karin R. ;
Rezaei, Nima ;
Grimbacher, Bodo ;
Lohrmann, Sabine ;
Sherkat, Roya ;
Klein, Christoph .
BLOOD, 2012, 119 (15) :3450-3457
[2]  
Alkhouri N, 2011, EXPERT REV GASTROENT, V5, P201, DOI [10.1586/EGH.11.6, 10.1586/egh.11.6]
[3]   Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1 [J].
An, Huazhang ;
Hou, Jin ;
Zhou, Jun ;
Zhao, Wei ;
Xu, Hongmei ;
Zheng, Yuejuan ;
Yu, Yizhi ;
Liu, Shuxun ;
Cao, Xuetao .
NATURE IMMUNOLOGY, 2008, 9 (05) :542-550
[4]   Biochemical analysis of MST1 kinase: Elucidation of a C-terminal regulatory region [J].
Anand, Ruchi ;
Kim, Ah-Young ;
Brent, Michael ;
Marmorstein, Ronen .
BIOCHEMISTRY, 2008, 47 (25) :6719-6726
[5]   Non-coding RNA networks in cancer [J].
Anastasiadou, Eleni ;
Jacob, Leni S. ;
Slack, Frank J. .
NATURE REVIEWS CANCER, 2018, 18 (01) :5-18
[6]   Neratinib is an MST1 inhibitor and restores pancreatic β-cells in diabetes [J].
Ardestani, Amin ;
Tremblay, Matthew S. ;
Shen, Weijun ;
Maedler, Kathrin .
CELL DEATH DISCOVERY, 2019, 5 (1)
[7]   Neratinib protects pancreatic beta cells in diabetes [J].
Ardestani, Amin ;
Li, Sijia ;
Annamalai, Karthika ;
Lupse, Blaz ;
Gerayandi, Shirin ;
Dobrowolski, Aleksandra ;
Yu, Shan ;
Zhu, Siying ;
Baguley, Tyler D. ;
Surakattula, Murali ;
Oetjen, Janina ;
Hauberg-Lotte, Lena ;
Herranz, Raquel ;
Awal, Sushil ;
Altenhofen, Delsi ;
Van Nguyen-Tran ;
Joseph, Sean ;
Schultz, Peter G. ;
Chatterjee, Arnab K. ;
Rogers, Nikki ;
Tremblay, Matthew S. ;
Shen, Weijun ;
Maedler, Kathrin .
NATURE COMMUNICATIONS, 2019, 10 (1)
[8]   Hippo Signaling: Key Emerging Pathway in Cellular and Whole-Body Metabolism [J].
Ardestani, Amin ;
Lupse, Blaz ;
Maedler, Kathrin .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2018, 29 (07) :492-509
[9]   The Hippo Signaling Pathway in Pancreatic β-Cells: Functions and Regulations [J].
Ardestani, Amin ;
Maedler, Kathrin .
ENDOCRINE REVIEWS, 2018, 39 (01) :21-35
[10]   MST1: a promising therapeutic target to restore functional beta cell mass in diabetes [J].
Ardestani, Amin ;
Maedler, Kathrin .
DIABETOLOGIA, 2016, 59 (09) :1843-1849
12345678910